You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Medtronic
Harvard Business School
Merck
Colorcon

Last Updated: April 11, 2021

DrugPatentWatch Database Preview

Litigation Details for ViiV Healthcare UK Ltd. v. Lupin Ltd. (D. Del. 2011)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in ViiV Healthcare UK Ltd. v. Lupin Ltd.
The small molecule drugs covered by the patent cited in this case are   Start Trial ,   Start Trial , and   Start Trial .

Details for ViiV Healthcare UK Ltd. v. Lupin Ltd. (D. Del. 2011)

Date Filed Document No. Description Snippet Link To Document
2011-06-29 1 Complaint United States Patent No. 6,417,191 (“the ‘l9l patent”). This action is based upon the Patent Laws of the…§ l39l(b) and (c), and l400(b). THE PATENT 13. The ‘191 patent, entitled “Synergistic Combinations of…the ‘191 patent including the right to sue and to recover for any infringement of that patent, A true …during the term of the ‘191 patent, it would further infringe that patent under 35 U.S.C. § 271(a), (b…during the term of the ‘191 patent, it would further infringe the ‘191 patent under 35 U.S.C. § 271(a), External link to document
2012-11-15 126 Opinion Healthcare Co. assert U.S. Patent No. 6,417,191 ('" 191 Patent") against Defendants Lupin… Teva Pharmaceuticals, USA, Inc. 1 The '191 Patent relates to therapeutic combinations of anti-HIV… Construction Construction from Patent-in-Suit "(IS, 4R)- Plain and… Construction Construction Patent-in-Suit "combination" Plain… Construction Construction Patent-in-Suit "pharmaceutical Plain and External link to document
2013-07-12 210 POST Trial Brief Number (if applicable) ‘191 patent U.S. Patent No. 6,417,191 …purposes of patent infringement requires an element-by-element comparison of the patent claim and the…Product infringes any Asserted Claim of the ‘191 patent (4, 26, 27, 29, 30, 34, 36, 38, 39, and 47). …manufacture, use, or sale of the drug would infringe the patent “is properly grounded in the ANDA application and…. ViiV must show that “every limitation of the patent claim asserted” is satisfied “either literally External link to document
2013-07-16 216 Redacted Document collectively “Lupin”) infringement of U.S. Patent No. 6,417,191 (the “’191 patent”). Plaintiffs ViiV Healthcare…infringement case, ViiV presented the ’191 patent, portions of the ’191 patent’s prosecution history, the aforementioned…for a drug claimed in a patent or the use of which is claimed in a patent” if the ANDA applicant seeks…........ 13, 14 In re Alfuzosin Hydrochloride Patent Litig., No. 08-MD-1941, 2010 WL 1956286 …......... 5, 6, 13 In re Rosuvastatin Calcium Patent Litig., 719 F. Supp. 2d 388 (D. Del. 2010), External link to document
2013-12-16 257 Opinion ViiV") assert U.S. Patent No. 6,417,191 (''the' 191 Patent") against Defendants… '191 Patent is invalid as obvious. Lupin individually asserts that the '191 Patent is invalid…ofblocking patents. 38 Defendants main argument is that the existence of"blocking patents," owned… some appeal if the patent claims did not limit the term animal, here the patent claims explicitly limit…that the '161 Patent is not sufficiently enabled for a POSA to utilize the patent without undue experimentation External link to document
2014-01-27 276 Patent/Trademark Report to Commissioner the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,417,191. (Attachments: # 1 …2011 24 January 2014 1:11-cv-00576 830 Patent Defendant District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
AstraZeneca
Mallinckrodt
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.